BCM
Bayesian Capital Management’s Fate Therapeutics FATE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-17,174
| Closed | -$60.1K | – | 782 |
|
|
2024
Q3 | $60.1K | Buy |
+17,174
| New | +$60.1K | 0.01% | 620 |
|
|
2024
Q2 | – | Sell |
-39,800
| Closed | -$292K | – | 856 |
|
|
2024
Q1 | $292K | Buy |
39,800
+20,164
| +103% | +$148K | 0.03% | 557 |
|
|
2023
Q4 | $73.4K | Sell |
19,636
-18,600
| -49% | -$69.6K | 0.01% | 670 |
|
|
2023
Q3 | $81.1K | Sell |
38,236
-22,000
| -37% | -$46.6K | 0.01% | 622 |
|
|
2023
Q2 | $287K | Buy |
60,236
+31,900
| +113% | +$152K | 0.03% | 551 |
|
|
2023
Q1 | $162K | Buy |
28,336
+9,600
| +51% | +$54.7K | 0.02% | 636 |
|
|
2022
Q4 | $189K | Buy |
18,736
+3,900
| +26% | +$39.4K | 0.03% | 610 |
|
|
2022
Q3 | $332K | Buy |
+14,836
| New | +$332K | 0.07% | 385 |
|
|
2021
Q2 | – | Sell |
-6,300
| Closed | -$519K | – | 480 |
|
|
2021
Q1 | $519K | Buy |
+6,300
| New | +$519K | 0.12% | 223 |
|